Quantifying cytokine levels to differentiate between healthy and disease states...

Thanks to Larry Demejo an recently Retired Kodak Senior Researcher sent me this Article.

Originally Published IVDT November/December 2008
MOLECULAR DIAGNOSTICS
Adapting life sciences technologies to IVDsTechnological advances in life sciences can feed the early-stage assay development pipeline and can be transitioned into the clinical diagnostics setting.

Sara J. Agee and Quynh Anh Lu

It is nothing like have a great team in place to climb Mount Everest.

Technological advances in life sciences can feed the early-stage assay development pipeline and can be transitioned into the clinical diagnostics setting.

Quantifying cytokine levels to differentiate between healthy and disease states...

Measuring Healthy Cytokine Levels

"The life sciences effort toward developing diagnostics feeds the early-stage assay development pipeline, which can later be transitioned into the clinical setting. Singulex is currently focused on developing assays for cytokines, a complex family of secreted signaling molecules that trigger various responses from the immune system in a combinatorial manner. The level of secretion of specific cytokines can have implications for a variety of disease pathologies, including inflammation, cancer, diabetes, and autoimmune disorders.

However, baseline concentrations from the plasma of healthy human subjects for many cytokines have yet to be defined by prior assay technologies. Establishing such baseline levels of cytokines will provide an important comparison before validating levels across disease states associated with inflammation. This new information will benefit future development of diagnostics that use inflammation as an indicator for such diseases as rheumatoid arthritis, autoinflammatory disease, and asthma.
Some studies have also shown a role for cytokines in staging and/or diagnosing cancer.9 For example, based on the Luminex platform, the Bio-Plex assay by Bio-Rad Laboratories Inc. (Hercules, CA) has been used to implicate elevated IL-6, IL-17, and G-CSF as indicative of breast cancer–positive patients.10 The benefit of this technology is the ability to multiplex, so a large number of cytokines were surveyed. However, this outcome came at the expense of sensitivity, and as a result, this study did not include levels from healthy subjects free of any symptoms. Better, more-sensitive immunoassay technologies could improve the clinical relevance and diagnostic value of these biomarkers in the future."

Quantifying cytokine levels to differentiate between healthy and disease states


What a way to start the New year.

If they Measure the Cytokine levels in Melanoma Patients, and find that they are deficient, they can start CLTA-4 or Li-2 or Adaptive Cell therapy. The Onlogogist has a starting reference point. It will give the oncologist some insight.

Way to go Larry!!!!!!!

Now that is team work!!!!!

Jimmy B